CN102257009A - 具有针对dc-sign的结合特异性的配体 - Google Patents

具有针对dc-sign的结合特异性的配体 Download PDF

Info

Publication number
CN102257009A
CN102257009A CN2009801529594A CN200980152959A CN102257009A CN 102257009 A CN102257009 A CN 102257009A CN 2009801529594 A CN2009801529594 A CN 2009801529594A CN 200980152959 A CN200980152959 A CN 200980152959A CN 102257009 A CN102257009 A CN 102257009A
Authority
CN
China
Prior art keywords
lip1
seq
sign
variable domain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801529594A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·德维尔德特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domantis Ltd
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of CN102257009A publication Critical patent/CN102257009A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN2009801529594A 2008-10-21 2009-10-19 具有针对dc-sign的结合特异性的配体 Pending CN102257009A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
US61/107085 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (1)

Publication Number Publication Date
CN102257009A true CN102257009A (zh) 2011-11-23

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801529594A Pending CN102257009A (zh) 2008-10-21 2009-10-19 具有针对dc-sign的结合特异性的配体

Country Status (16)

Country Link
US (1) US20110257373A1 (cg-RX-API-DMAC7.html)
EP (1) EP2356149A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012506237A (cg-RX-API-DMAC7.html)
KR (1) KR20110071139A (cg-RX-API-DMAC7.html)
CN (1) CN102257009A (cg-RX-API-DMAC7.html)
AR (1) AR073905A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009306424A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0919714A2 (cg-RX-API-DMAC7.html)
CA (1) CA2740856A1 (cg-RX-API-DMAC7.html)
EA (1) EA201100488A1 (cg-RX-API-DMAC7.html)
IL (1) IL212086A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011004244A (cg-RX-API-DMAC7.html)
TW (1) TW201019962A (cg-RX-API-DMAC7.html)
UY (1) UY32189A (cg-RX-API-DMAC7.html)
WO (1) WO2010046337A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102763B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125271A1 (zh) * 2022-12-13 2024-06-20 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004245A (es) * 2008-10-21 2011-09-06 Domantis Ltd Composicion para dirigirse a las celulas dendriticas.
US9481724B2 (en) * 2011-12-19 2016-11-01 The Rockefeller University hDC-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
JP5185624B2 (ja) * 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体
EP1966242A1 (en) * 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
EP2077863A4 (en) * 2006-10-31 2010-10-06 Domantis Ltd intrabodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SI J,ET AL.: "ACCESSION NO:AY73916.1,anti-Toxoplasma gondii SAG1 immunoglobulin S3 light chain variable region partial", 《GENBANK DATABASE》 *
杨帆,杨秀荣: "表面等离子体共振技术在分子生物学中的应用", 《生物工程学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125271A1 (zh) * 2022-12-13 2024-06-20 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Also Published As

Publication number Publication date
JP2012506237A (ja) 2012-03-15
CA2740856A1 (en) 2010-04-29
KR20110071139A (ko) 2011-06-28
UY32189A (es) 2010-05-31
EA201100488A1 (ru) 2011-12-30
ZA201102763B (en) 2012-09-26
AU2009306424A1 (en) 2010-04-29
MX2011004244A (es) 2011-05-25
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
WO2010046337A3 (en) 2010-07-01
AR073905A1 (es) 2010-12-09
WO2010046337A2 (en) 2010-04-29
EP2356149A2 (en) 2011-08-17
BRPI0919714A2 (pt) 2015-12-08
TW201019962A (en) 2010-06-01

Similar Documents

Publication Publication Date Title
US12428497B2 (en) Multispecific antibody constructs
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
CN110831626B (zh) 单价抗备解素抗体及抗体片段
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2010505436A (ja) コンディショナルな方法で所望の分子に結合するアミノ酸配列
CN105121467A (zh) 抗cd47抗体及其使用方法
KR20070084069A (ko) Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
EA035517B1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CN115109156A (zh) 一种靶向bcma的纳米抗体及其应用
CN114685666B (zh) 抗间皮素纳米抗体及其应用
TWI906795B (zh) 特異性結合Claudin 18.2的抗體及其製法和應用
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
WO2023142297A1 (zh) Muc1结合分子及其应用
US20110257373A1 (en) Ligands that have binding specificity for dc-sign
WO2024094076A1 (zh) 一种gipr结合蛋白及其应用
WO2023051618A1 (zh) Ctla-4结合分子及其应用
CN106062193A (zh) 新型与人tlr2及人tlr4结合的双特异性抗体
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
WO2023011650A1 (zh) 一种多特异性抗体及其用途
RU2784673C2 (ru) Конструкции полиспецифических антител
JP2025528101A (ja) 多重特異性ポリペプチド複合体
HK40089568A (en) Novel cancer immunotherapy antibody compositions
CN120769865A (zh) 结合分子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111123